Development of phosphorylated glucomannan-coated chitosan nanoparticles as nanocarriers for protein delivery

被引:47
作者
Cuna, M.
Alonso-Sande, M.
Remunan-Lopez, G.
Pivel, J. P.
Alonso-Lebrero, J. L.
Alonso, M. J. [1 ]
机构
[1] Univ Santiago de Compostela, Fac Pharm, Dept Pharm & Pharmaceut Technol, Santiago De Compostela, Spain
[2] Ind Farmaceut Cantabria SA, R&D Dept, Madrid, Spain
关键词
chitosan; glucomannan; Inmunoferon (R); nanoparticles; oral administration; protein delivery;
D O I
10.1166/jnn.2006.435
中图分类号
O6 [化学];
学科分类号
0703 [化学];
摘要
The aim of the present work was to develop a new nanoparticle carrier, adapted for the oral administration of proteins and their delivery to the immune system. Chitosan and phosphorylated glucomannan were chosen as major constituents of the nanoparticles. Chitosan nanoparticles were formed by ionic gelation and then coated with glucomannan. Two different protocols were adopted for the formation of the glucomannan coating: protocol I, in which chitosan nanoparticles were isolated before their coating; protocol II, in which chitosan nanoparticles were not isolated, but coated with glucomannan in the presence of free chitosan. The results showed that, under the selected formulation conditions, the sizes of the nanoparticles ranged between 170 and 300 nm and their zeta potential values were inverted from positive to negative by the glucomannan coating. The nanoparticles prepared by the two protocols could be freeze-dried, in the presence or absence of cryoprotective agents, preserving their original characteristics. The results of the stability study evidenced the positive role of the glucomannan coating in preventing the aggregation of the nanoparticles in buffered media. Finally, the association of the inmunomodulatory protein complex P1 to the chitosan-glucomannan nanoparticles was investigated. The results showed that the association was not dependent on the chitosan: sodium tripoliphosphate ratio, but it was significantly affected by the presence of sodium phosphate in the protein structure.
引用
收藏
页码:2887 / 2895
页数:9
相关论文
共 33 条
[1]
EFFECT OF SHORT-TERM INGESTION OF KONJAC GLUCOMANNAN ON SERUM-CHOLESTEROL IN HEALTHY-MEN [J].
ARVILL, A ;
BODIN, L .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1995, 61 (03) :585-589
[2]
BEHRENS I, 2002, PHARM RES, V19, P8
[3]
Inmunoferon®, a glycoconjugate of natural origin, inhibits LPS-induced TNF-α production and inflammatory responses [J].
Brieva, A ;
Guerrero, A ;
Alonso-Lebrero, JL ;
Pivel, JP .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2001, 1 (11) :1979-1987
[4]
Calvo P, 1997, J APPL POLYM SCI, V63, P125, DOI 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO
[5]
2-4
[6]
Chitosan and chitosan ethylene oxide propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines [J].
Calvo, P ;
RemunanLopez, C ;
VilaJato, JL ;
Alonso, MJ .
PHARMACEUTICAL RESEARCH, 1997, 14 (10) :1431-1436
[7]
THE HOFMEISTER EFFECT AND THE BEHAVIOR OF WATER AT INTERFACES [J].
COLLINS, KD ;
WASHABAUGH, MW .
QUARTERLY REVIEWS OF BIOPHYSICS, 1985, 18 (04) :323-422
[8]
NANOCAPSULES AS CARRIERS FOR ORAL PEPTIDE DELIVERY [J].
DAMGE, C ;
MICHEL, C ;
APRAHAMIAN, M ;
COUVREUR, P ;
DEVISSAGUET, JP .
JOURNAL OF CONTROLLED RELEASE, 1990, 13 (2-3) :233-239
[9]
The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent [J].
Desai, MP ;
Labhasetwar, V ;
Walter, E ;
Levy, RJ ;
Amidon, GL .
PHARMACEUTICAL RESEARCH, 1997, 14 (11) :1568-1573
[10]
Gastrointestinal uptake of biodegradable microparticles: Effect of particle size [J].
Desai, MP ;
Labhasetwar, V ;
Amidon, GL ;
Levy, RJ .
PHARMACEUTICAL RESEARCH, 1996, 13 (12) :1838-1845